Trial · NCT03457701
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO | Up to Day 57 | Evaluable Population consisted of all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. | Percentage (%) of iron absorbed | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Serum Iron Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Micromoles per liter (umol/L) | MEAN |
| SECONDARY | Period 1 and 2: Change From Baseline in Transferrin Following Treatment With Daprodustat or rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Gram per Liter (g/L) | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Transferrin Saturation Following Treatment With Daprodustat or rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Percentage (%) of transferrin saturation | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Soluble Transferrin Receptor Following Treatment of Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Milligrams per liter (mg/L) | MEAN |
| SECONDARY | Periods 1 and 2: Ratio to Baseline in Ferritin Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Microgram per liter (ug/L) | GEOMETRIC_MEAN |
| SECONDARY | Periods 1 and 2: Ratio to Baseline (Day 1) in Hepcidin Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Microgram per liter (ug/L) | GEOMETRIC_MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Erythroferrone Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Microgram per liter (ug/L) | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Hemoglobin Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Grams per liter (g/L) | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Hematocrit Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Proportion of red blood cells in blood | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Erythrocytes Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | 10^12 cells/liter | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Erythrocyte Mean Corpuscular Volume Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Femtoliter (fL) | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Reticulocyte Hemoglobin Following Treatment of Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | Picogram (pg) | MEAN |
| SECONDARY | Periods 1 and 2: Change From Baseline in Reticulocytes Following Treatment With Daprodustat and rhEPO | Baseline (Day 1), Day 14 and Day 28 in treatment periods 1 and 2 (each period is of 28 days) | Evaluable Population that included all randomized participants who received study medication and completed the iron absorption assessment for both treatment periods. Only those participants with data available at the specified data points were analyzed. | 10^12 cells/liter | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03457701/outcomes